Teva Santé, Paris La Défense, France.
Eur Rev Med Pharmacol Sci. 2009 Sep-Oct;13(5):323-30.
Poor inhalation technique may impact both asthma control and compliance in patients with asthma. The SYSTER survey is therefore aimed at assessing the influence of starting or switching an existing therapy to a breath-actuated pressurized metered dose inhaler (pMDI, Autohaler) on these parameters.
709 French general practitioners (GP) enrolled 2588 asthmatic patients in whom therapy with the breath-actuated pMDI was either initiated, or a switch from an existing inhalation device to the said inhaler was deemed necessary. Asthma control was assessed at inclusion and after 4 weeks of treatment with the Juniper Asthma Control Questionnaire (ACQ). In addition, patient adherence was estimated according to the self-reported Morisky scale.
1510 patients (mean age 39 years, standard deviation 18 years; 53% male) completed follow-up after 4 weeks. The main reasons for inhaler change were poor asthma control (49%) and poor coordination (40%). After 4 weeks of therapy with the breath-actuated pMDI, asthma control significantly improved from 2.35 +/- 1.05 to 1.32 +/- 0.93 in the ACQ (p < 0.0001). Also, self-reported patient adherence improved from 2.11 +/- 1.43 to 1.57 +/- 1.53 on the Morisky scale (p < 0.0001).
These results suggest that by focusing on the inhalation devices, asthma control and compliance with treatment are improved.
吸入技术不佳可能会影响哮喘患者的哮喘控制和治疗依从性。因此,SYSTER 调查旨在评估起始或转换现有治疗方案为气动式压力定量吸入器(pMDI,Autohaler)对这些参数的影响。
709 名法国全科医生(GP)招募了 2588 名哮喘患者,其中部分患者起始气动式 pMDI 治疗,部分患者因现有吸入设备无法满足需求而需转换为该吸入器。采用 Juniper 哮喘控制问卷(ACQ)在纳入时和治疗 4 周后评估哮喘控制情况。此外,根据 Morisky 自我报告量表估计患者的治疗依从性。
1510 名患者(平均年龄 39 岁,标准差 18 岁;53%为男性)在治疗 4 周后完成了随访。改变吸入器的主要原因是哮喘控制不佳(49%)和协调能力差(40%)。使用气动式 pMDI 治疗 4 周后,ACQ 评分从 2.35±1.05 显著改善至 1.32±0.93(p<0.0001)。Morisky 量表上的自我报告治疗依从性也从 2.11±1.43 改善至 1.57±1.53(p<0.0001)。
这些结果表明,通过关注吸入装置,可改善哮喘控制和治疗依从性。